Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
admitting, adult, Alberta, American, anticoccidial, antidepressant, Antonacci, assembling, Baicker, baricitinib, baseline, birth, BPH, Brewer, CAFC, CETP, cholesteryl, circumvented, consultant, Counsel, differentiation, disclaim, DLBCL, EGFR, endothelial, Epp, EPS, ester, Evacetrapib, expressly, faith, filling, Harrington, hemoglobin, hydrochloride, IIb, IMAGINE, indefinite, infrequent, JAK, Katherine, Kentucky, lack, leave, maker, Maxiban, Melissa, mentioned, mg, Micotil, Monteban, neuritic, Optaflexx, PKC, Poland, pooled, psoriatic, Pulmotil, radioactive, read, Reapproval, reassuming, regimen, reinstatement, reliance, revocation, revolving, Saavedra, sitagliptin, speak, steep, strict, suffering, survival, Symbyax, tabalumab, tiered, tomography, TrazentaTM, tyrosine, underway, undue, unfunded, unmet, uptake, valuable, vascular, vitamin, Walmart, website, wellbeing, Whyte
Removed:
add, adequately, Alaska, alfred, allocate, amended, arnold, Asian, asThe, atomoxetine, Aurobindo, BI, Bookto, Bryce, Carmine, caution, certified, Connecticut, coupled, Deane, death, duly, duty, EDNY, Elizabeth, ellen, erik, evenly, exceeded, explained, Fecho, federally, feldstein, finance, forecast, Frameworkissued, Frank, franklyn, furnished, fyrwald, gilman, glycemic, grew, guaranteed, guilty, hanish, harbor, heard, Honorable, horn, inapplicable, inInternal, insured, inThe, intramuscular, Jack, karen, Kowa, marram, martin, mature, MDL, Michele, monitoring, Mylan, nationwide, negative, obesity, obligated, omitted, overturned, partial, Pennsylvania, permission, population, prendergast, proceeding, purporting, recovery, redeemed, reducing, refer, refund, Relprevv, rigid, rounding, Sandoz, scientific, separated, SmithKline, statin, step, succeeding, Sun, symbol, thereunto, toThe, tradename, underinsured, undersigned, unemployment, USA, warned, Weinstein, Wyeth
Filing tables
Filing exhibits
- 10-K Annual report
- 10.11 Arrangement Regarding Retirement Benefits for Robert A. Armitage
- 12 Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 21 List of Subsidiaries
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13A-14(A) Certification of President and Chief Executive Officer
- 31.2 Rule 13A-14(A) Certification of Chief Financial Officer
- 32 Section 1350 Certification
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 12. Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
ELI LILLY AND COMPANY AND SUBSIDIARIES
Years Ended December 31, | ||||||||||||||||||||
2012 | 2011 | 2010 | 2009 | 2008 | ||||||||||||||||
(Dollars in millions) | ||||||||||||||||||||
Consolidated pretax income (loss) | $ | 5,408.2 | $ | 5,349.5 | $ | 6,525.2 | $ | 5,357.8 | ($1,307.6 | ) | ||||||||||
Interest(1) | 198.8 | 211.7 | 211.5 | 291.5 | 276.5 | |||||||||||||||
Less interest capitalized during the period | (21.0 | ) | (25.7 | ) | (26.0 | ) | (30.2 | ) | (48.2 | ) | ||||||||||
Earnings (loss) | $ | 5,586.0 | $ | 5,535.5 | $ | 6,710.7 | $ | 5,619.1 | ($1,079.3 | ) | ||||||||||
Fixed charges | $ | 198.8 | $ | 211.7 | $ | 211.5 | $ | 291.5 | $ | 276.5 | ||||||||||
Ratio of earnings (loss) to fixed charges | 28.1 | 26.1 | 31.7 | 19.3 | NM(2) |
NM – Not Meaningful
1 | Interest is based upon interest expense reported as such in the consolidated statements of operations and does not include any interest related to unrecognized tax benefits, which is included in income tax expense. |
2 | For such ratio, earnings were $1.31 billion less than fixed charges. The loss for the year ended December 31, 2008, included special charges of $1.48 billion related to the settlement of a U.S. government investigation of our marketing practices for Zyprexa, and acquired in-process research and development expense of $4.69 billion associated with the ImClone acquisition. |